Ingenuity Systems And Laboratory Corporation Of America Announce Molecular Diagnostic Collaboration

Companies to collaborate on the development of bioinformatics tools for clinical sequencing.

Redwood City, CA /PRNewswire/ -- Ingenuity® Systems, a leading provider of biomedical information and analysis solutions, and Laboratory Corporation of America® Holdings (LabCorp®) today announced a long term collaboration for LabCorp to license and deploy Ingenuity's clinical content and applications to rapidly review and annotate clinically relevant sequence variations.

The new solution will leverage the comprehensive, expert-curated Ingenuity Knowledge Base of biomedical content, including an up-to-date database of all human disease phenotype associated variants. The variant knowledge base will be delivered through a cloud-based application optimized for rapid and accurate variant interpretation.

"Next generation sequencing is poised to transform the molecular diagnostic market, but the opportunity is gated by the urgent need for an optimized and scalable solution for interpreting and scoring clinical variants," said Jake Leschly, CEO of Ingenuity Systems. "Ingenuity has developed the information infrastructure, curated content, and cloud-based applications to address this need and we are very fortunate to be able to partner with LabCorp to further evolve the solution and be part of their vision and strategy for molecular diagnostics."

About Ingenuity® Systems
Ingenuity® Systems is a leading provider of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems in life science research and molecular diagnostics. Today, Ingenuity's solutions are used by tens of thousands of researchers and clinicians at hundreds of leading pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide.